Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia
EudraCT number 2013-003313-17
Protocol number GS-US-312-0123
Sponsor Gilead Sciences, Inc.,333 Lakeside Drive,Foster City, CA,94404
Indications Hemato-oncology
Diagnosis Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2014
Date of approval by Institute (SÚKL) 4.6.2014
Date of approval by EC 4.6.2014
Date of initiation CT in ČR 18.8.2014
Date of ending CT in ČR 23.3.2016 & 27.6.2016
Notice
Sites Vseobecna fakultni nemocnice v Praze,1. interni klinika - klinika hematologie,U nemocnice 1,Praha 2,128 08
Fakultni nemocnice Hradec Kralove,IV. interni hematologicka klinika,Sokolská 581,Hradec Kralove,500 05
Fakultni nemocnice Kralovske Vinohrady,Interni hematologicka klinika,Srobarova 50,Praha 10,100 34
Fakultni nemocnice Brno,Interni hematoonkologicka klinika,Jihlavská 20,Brno,625 00
Fakultni nemocnice Plzen,Hemato-onkologicke oddeleni,Alej Svobody 80,Plzen,304 60
Fakultni nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790,Ostrava,708 52

‹‹ Back to list